Immunology & Inflammation

Accord Healthcare ranks among the fastest-growing generic and biosimilar medicines companies in Europe, distributing products across more than 80 countries and holding one of the largest market footprints of any European generic pharmaceutical business. Established as the European commercial arm of Intas Pharmaceuticals, an Indian pharmaceutical group headquartered in Ahmedabad, Accord operates its principal EMENA base from Uxbridge, United Kingdom, with additional commercial representation in Barcelona, Spain, and a growing network of affiliates across Eastern Europe. Therapeutic Portfolio and European Reach Accord's product portfolio is built around hospital and community settings across several key therapy areas. Its oncology and haematology range forms the largest segment of the business, complemented by lines covering autoimmune conditions and central nervous system disorders. The company has delivered successive year-on-year growth in the volume of medicines launched across European markets, with its most recent annual cycle yielding the largest portfolio rollout in the company's history. A dedicated European affiliate network, with national teams across Austria, Czech Republic, Finland, France, Germany, Ireland, Italy, the Netherlands, Poland, Romania, Slovakia, Spain and Sweden, provides the commercial infrastructure to support hospital tenders and retail pharmacy channels simultaneously. Biosimilars, Animal Health and Sustainability Beyond small-molecule generics, Accord Healthcare operates at the higher-complexity end of pharmaceutical development through its biosimilars programme, where regulatory pathways and development timelines mirror those of originator biologics. This positions the company among a relatively small group of European generics firms capable of competing in both chemical and biological medicine categories. Accord also maintains an animal health division, extending the group's reach across the broader life sciences sector, alongside a patient advocacy group function that signals engagement with patient outcomes beyond the purely commercial. The company publishes environment, social and governance reporting in line with expectations from institutional partners and regulated healthcare customers across the European Union and beyond. Further information is available at accord-healthcare.com.

Anchored in the science of human plasma, ADMA Biologics operates as a fully vertically integrated commercial biopharmaceutical company applying patented immunotechnology to develop, manufacture, and commercialise plasma-derived biologics for patients with serious immunological disorders. Listed on NASDAQ (ticker: ADMA) and headquartered in Boca Raton, Florida, the company controls each stage of its supply chain, from plasma collection through fill-finish manufacturing and medical affairs, a model that sets it apart from conventional pharmaceutical manufacturers dependent on external plasma suppliers. Commercial Portfolio and Plasma Collection ADMA's marketed products include ASCENIV, an intravenous immunoglobulin (IVIG) indicated for primary humoral immunodeficiency in adults and adolescents; BIVIGAM, a broad-spectrum IVIG therapy; and Nabi-HB, a hyperimmune globulin targeting hepatitis B. These products are manufactured at the company's FDA-licensed facility in Boca Raton. Plasma supply is secured through ADMA BioCenters, its own network of plasma collection centres operating across the United States, which feed proprietary immunotechnology fractionation processes downstream. Contract development and manufacturing services extend the company's commercial reach, allowing third-party biopharmaceutical partners to access ADMA's specialised biologics processing infrastructure. Scientific direction is guided by a dedicated Scientific Advisory Board, and the medical affairs function supports clinician engagement, publications, and advocacy for patients living with primary immunodeficiency disease. Further information is available at admabiologics.com.

Specialising in osteoarticular and inflammation-focused research, AGINKO operates as a contract research organisation (CRO) with a defined focus that distinguishes it from broader-scope service providers. The company concentrates on the musculoskeletal segment, deploying a team of experienced musculoskeletal experts to guide orthopaedic products and compounds through pre-clinical and clinical development pathways. Based in Marly, Switzerland, AGINKO Research AG serves clients across the pharmaceutical, biotechnology, and medical device industries. Its stated mission is to deliver high-quality pre-clinical laboratory services and clinical trial management with a commitment to both customer service and scientific rigour. The combination of pre-clinical and clinical capability within a single specialist organisation allows clients to progress compounds along the regulatory pathway without transferring to a separate provider at each stage. The company's service portfolio spans preclinical research, including disease models; clinical research services; histology and laboratory services; medical consultation and referral; and consulting covering due diligence. Histology services represent a particular operational capability, with preclinical histology slide processing cited among the company's operational activities. Regulatory and clinical process guidance for orthopaedic compounds is a core offering, reflecting the organisation's specialist positioning in the osteoarticular field. AGINKO serves clients globally across multiple countries, providing an international reach from its Swiss base. The company's focus on a defined therapeutic area, rather than a generalist CRO approach, positions it as a reference partner for organisations developing products in musculoskeletal and inflammatory conditions. Further information is available at aginko.com.

Dedicated entirely to Phase II-IV clinical trials , Albuquerque Clinical Trials has operated as a locally owned, independent research centre since 1988. Based in Albuquerque, New Mexico, the site conducts studies on behalf of pharmaceutical and biotechnology sponsors across a broad range of therapeutic areas. The facility's in-house team brings together board-certified physicians, a PharmD, certified study coordinators, licensed clinicians, regulatory specialists, recruitment professionals and data entry personnel. This integrated staffing model allows the centre to manage all phases of a trial from a single site, reducing sponsor coordination burden and supporting consistent data quality. The active study portfolio covers a diverse set of indications, including type I and type II diabetes , obesity-related conditions, weight loss, gout, heart failure prevention, systemic lupus erythematosus, coeliac disease, migraines, male incontinence, constipation and infectious disease, including a C. difficile vaccine programme. Birth control and menstrual migraine studies are also listed among current or recent therapeutic areas, reflecting the breadth of the clinical programme. The centre states its core commitments as exceeding sponsor expectations for dependability, human protection, subject enrolment and overall performance, with the broader aim of improving patient health through access to innovative therapies. Patient-facing infrastructure includes a dedicated sign-up pathway and a sponsor referral channel. Further information is available at abqct.com.

Allergy Therapeutics positions itself as a global pioneer of convenient treatment for allergy and immune-related disorders, operating as a publicly listed company (PLC) with commercial presence across Austria, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom. A declared focus on patient convenience runs throughout the company's scientific and commercial model. The organisation frames convenience not as a secondary benefit but as a clinical imperative, recognising that treatment adherence in allergy immunotherapy depends on how manageable the regimen is for both healthcare professionals and patients. Its research and development programme reflects this, combining product development with a published body of investigator and consultant registry data. The company's adjuvant technology is commercialised through its Bencard Adjuvant Systems division, which sits alongside the core Allergy Therapeutics brand as a specialist unit serving healthcare partners and industry stakeholders. This dual structure signals a role that extends beyond direct-to-clinician supply into platform licensing and scientific collaboration. Investor-facing materials describe a defined business model, investment case, and strategy, consistent with a company that reports to public markets and maintains structured shareholder services. The breadth of its European footprint and the existence of a dedicated healthcare professional information channel indicate an established B2B and clinical relationships network. Further information is available at allergytherapeutics.com.

ASLAN Pharmaceuticals is a dual-listed (NASDAQ: ASLN; Taiwan Stock Exchange) clinical-stage biopharmaceutical company headquartered in Singapore, with operations in Taiwan and the United States. Founded in 2010, the company concentrates its pipeline on inflammatory diseases and oncology, with a particular strategic emphasis on conditions where patients lack effective treatment options. The company's lead asset is farudodstat (ASLAN004), a monoclonal antibody that blocks both the IL-13 receptor alpha-1 and IL-4 receptor alpha subunits. This dual mechanism is designed to address the full spectrum of type 2 inflammation and is being evaluated in moderate-to-severe atopic dermatitis and ulcerative colitis. ASLAN Pharmaceuticals has conducted Phase 2 studies across these indications, with clinical data guiding its ongoing development strategy. Pipeline Focus and Business Model ASLAN Pharmaceuticals operates a capital-light model, progressing internally discovered compounds through clinical proof-of-concept before seeking regional or global partnership arrangements. The company has previously evaluated oncology assets including varlitinib, a pan-ErbB inhibitor studied in biliary tract cancer and gastric cancer, and retains scientific capabilities across both immunology and oncology drug discovery. With its Asia-Pacific base, ASLAN is positioned to run efficient clinical programmes in markets with high patient enrolment potential, supporting faster data generation across its therapeutic areas. Further information is available at aslanpharma.com.

AstraZeneca is one of the world's largest biopharmaceutical companies , with its global headquarters at the Cambridge Biomedical Campus in England. Founded in 1999 through the merger of Astra AB of Sweden and Zeneca Group of the United Kingdom, the company is listed on the London Stock Exchange (AZN) and on Nasdaq, and employs approximately 90,000 people across more than 100 countries. Cambridge functions not merely as a corporate address but as the centre of the company's worldwide research and early development capability, hosting thousands of scientists working across discovery biology, chemistry, and translational medicine. Therapy Areas and Pipeline The company's research strategy concentrates on three main therapy area clusters: oncology, cardiovascular, renal and metabolic disease (CVRM), and respiratory and immunology (R&I). Within oncology, AstraZeneca markets established medicines including osimertinib (Tagrisso), olaparib (Lynparza, developed with MSD), and durvalumab (Imfinzi). The CVRM portfolio includes dapagliflozin (Farxiga/Forxiga), which has received regulatory approvals across heart failure, chronic kidney disease, and type 2 diabetes indications. The respiratory franchise covers budesonide/formoterol combinations and the biologic tezepelumab (Tezspire, developed with Amgen) for severe asthma. UK Operations and Clinical Development AstraZeneca UK operates across the full pharmaceutical value chain: early and late-stage clinical trials , regulatory affairs, medical affairs, market access, and commercial operations serving the National Health Service. The UK site at Cambridge is complemented by manufacturing and biologics development capabilities at sites including Macclesfield. The company collaborates extensively with the Medical Research Council, Cancer Research UK, and NHS England, and was a prominent partner in the University of Oxford COVID-19 vaccine programme, through which AstraZeneca's Vaxzevria was manufactured and distributed globally at no profit during the pandemic period. AstraZeneca participates in hundreds of sponsored clinical studies in the United Kingdom at any given time, engaging NHS trusts, academic medical centres, and independent research sites. The organisation also operates a patient access programme infrastructure and maintains a dedicated UK medical information service for healthcare professionals. Further information is available at astrazeneca.co.uk.

Emergex Vaccines is a UK-based clinical-stage biotechnology company developing a new class of synthetic peptide vaccines designed to stimulate cytotoxic T-lymphocyte (CTL) responses rather than the antibody-driven immunity targeted by conventional vaccines. Founded in 2015 and headquartered in Abingdon, Oxfordshire, the company was established on the premise that T-cell immunity offers broader and more durable protection against rapidly mutating viral pathogens, including pandemic influenza strains and other emerging infectious threats. Platform Technology and Pipeline The company's core platform centres on short synthetic peptide constructs derived from conserved viral protein sequences. Because these sequences change little across viral variants, the approach aims to produce vaccines with cross-strain efficacy, addressing a central limitation of seasonal influenza vaccines that must be reformulated annually. Emergex has advanced candidates targeting influenza A and dengue fever through early-phase clinical evaluation, with additional programmes directed at other flaviviruses and respiratory viruses. Development and Funding Background Emergex has received support from UK public funding bodies and private investors to progress its pipeline from pre-clinical research into Phase I clinical trials. The company operates under a largely asset-light model, collaborating with contract research organisations and academic partners to conduct clinical work. As a private company, Emergex does not carry a public stock listing. Its programmes are positioned within the broader landscape of next-generation vaccine development , addressing unmet needs in both seasonal infectious disease management and pandemic preparedness. Further information is available at emergexvaccines.com.

Pioneering second-generation complement therapeutics , Invizius is a Scottish biotech company dedicated to improving outcomes for patients with autoimmune and inflammatory disorders, with a primary clinical focus on individuals undergoing extracorporeal treatments, including haemodialysis, cardiopulmonary bypass, and extracorporeal membrane oxygenation (ECMO). These patient groups face significant complement-driven complications that existing therapies fail to adequately address, leaving a well-documented gap in clinical care. Complement Biology and the PspCN Platform The company's core scientific platform centres on PspCN, a naturally derived complement regulator that modulates the complement cascade, a key component of the innate immune system implicated in systemic inflammation and tissue injury during extracorporeal procedures. PspCN serves as the foundation of Invizius's therapeutic pipeline and distinguishes the company from first-generation complement inhibitors that act on different pathway nodes. The approach targets the specific clinical settings where uncontrolled complement activation causes measurable patient harm. Invizius draws on a clinical and scientific advisory board with expertise spanning nephrology, cardiac surgery, and immunology, and is supported by an investor and collaborator network suited to its early-stage development model. The company's pipeline has progressed towards clinical trials, reflecting growing confidence in the PspCN mechanism and its applicability across extracorporeal indications. Incorporated and registered in Scotland, Invizius Limited (SC586903) operates from Edinburgh, with its registered office at Orchard Brae House, 30 Queensferry Road, EH4 2HS. The company is registered for VAT in the United Kingdom. Further information is available at invizius.com.

Founded by Paul Janssen in Beerse, Belgium in 1953 and now operating as the pharmaceutical division of Johnson Johnson, Janssen Global stands among the world's foremost research-driven pharmaceutical organisations. The business concentrates scientific and commercial resources on discovering, developing and delivering transformative medicines across oncology, immunology, infectious diseases and neuroscience, with a particularly strong record in haematological malignancies and autoimmune conditions. Therapeutic Focus and Pipeline Depth Janssen's approved portfolio illustrates the breadth of its therapeutic reach. In oncology and haematology , Darzalex (daratumumab) has become a standard-of-care option across multiple myeloma lines, while Imbruvica (ibrutinib), developed in collaboration with AbbVie, is approved across several B-cell malignancies. Zytiga (abiraterone acetate) remains a recognised treatment in metastatic prostate cancer. In immunology, Stelara (ustekinumab) and Tremfya (guselkumab) address moderate-to-severe plaque psoriasis and other inflammatory conditions. The neuroscience portfolio includes Spravato (esketamine), a nasal-spray formulation approved for treatment-resistant depression in adults. HIV and tuberculosis medicine reflects a long-standing infectious disease commitment carried through products such as Edurant (rilpivirine) and contribution to combination regimens used globally. Global Operations and Research Infrastructure Research and development hubs span Beerse, Spring House (Pennsylvania), La Jolla (California), Leiden in the Netherlands and Shanghai, supporting a pipeline that extends from early discovery through late-stage clinical programmes. Janssen works alongside academic medical centres, biotech partners and health systems to accelerate access. As a central component of Johnson Johnson's pharmaceutical segment, operating under the J J Innovative Medicine banner from 2023, the organisation benefits from the group's global manufacturing network, regulatory infrastructure and substantial annual R D investment. Its pharmaceutical pipeline spans both small molecules and large biologics, with active programmes in areas such as solid tumours, multiple sclerosis and pulmonary arterial hypertension. Further information is available at janssen.com.

Novavax, Inc. is a Gaithersburg, Maryland-based vaccine biotechnology company founded in 1987 and listed on NASDAQ (ticker: NVAX), best known for developing protein subunit vaccines using its proprietary Matrix-M adjuvant platform. Unlike mRNA or viral-vector approaches, Novavax produces recombinant nanoparticle antigens that mimic the surface of a pathogen, pairing them with Matrix-M, a saponin-based formulation derived from the Quillaja saponaria tree, to generate robust immune responses with a well-characterised tolerability profile. NVX-CoV2373 and COVID-19 Programme Novavax received its first major regulatory milestones through its COVID-19 vaccine, NVX-CoV2373, marketed as Nuvaxovid. The vaccine secured Emergency Use Authorisation from the US FDA, conditional marketing authorisation from the European Medicines Agency, and approvals in numerous countries across Asia-Pacific, Europe, and the Americas. Nuvaxovid became a significant addition to global vaccination campaigns as a protein-based alternative for individuals who preferred a non-mRNA option, with the World Health Organization granting it Emergency Use Listing. Updated formulations targeting later SARS-CoV-2 variants have continued to advance through regulatory review. Pipeline and Strategic Partnerships Beyond COVID-19, Novavax applies its platform to influenza vaccines , with a quadrivalent recombinant candidate in late-stage development, and combination respiratory programmes including a COVID-influenza co-formulation. The company has historically held collaboration agreements with the Coalition for Epidemic Preparedness Innovations (CEPI) and the Bill & Melinda Gates Foundation, and has executed manufacturing and supply partnerships with organisations including Serum Institute of India to support large-scale global distribution. Novavax's corporate growth strategy centres on out-licensing the Matrix-M adjuvant to third-party vaccine developers, extending the platform's reach across a broad range of infectious-disease targets. The company publishes peer-reviewed scientific findings through a dedicated publications resource and maintains transparency with the research and investment communities through its public filings and investor relations programme. Further information is available at novavax.com.

Founded in 1896 in Basel, Switzerland, Roche has spent more than a century developing medicines and diagnostic tests that together address some of the most complex conditions in modern healthcare. Listed on the SIX Swiss Exchange and a constituent of the Swiss Market Index, the company is one of the world's largest healthcare businesses by revenue. Operating across two complementary divisions, Pharma and Diagnostics, Roche occupies a distinctive position in the global industry: it is one of very few organisations that integrates therapeutic development with the in-vitro diagnostics capability to inform and monitor those same therapies. Therapeutic Focus Across Major Disease Areas Roche's pharmaceutical pipeline and marketed portfolio span a broad range of therapeutic areas, including oncology , haematology, neurology, ophthalmology, immunology, infectious diseases, inflammatory bowel diseases, cardiometabolic conditions, diabetes, respiratory disease, and women's health. This breadth reflects decades of investment in both internal research and external partnering, reinforced by the 2009 full acquisition of Genentech, which significantly expanded the company's biologics and personalised medicine capabilities. Roche maintains defined ethical standards and a structured innovation process to guide candidate selection and clinical development. Diagnostics as a Strategic Complement The Diagnostics division is widely recognised as the world's largest in-vitro diagnostics business and develops solutions that support clinical decision-making across many of the same disease areas addressed by the Pharma arm. Safety reporting infrastructure and dedicated support for safety officers form part of the diagnostic solutions offering, reinforcing the company's commitment to pharmacovigilance and patient safety throughout the product lifecycle. This integration of drug and diagnostic development is a long-standing strategic pillar at Roche, enabling a personalised healthcare approach that aligns diagnostic insight with therapeutic intervention. Governance at Roche is structured around a Board of Directors, an Executive Committee, and formal board committees, with an Annual General Meeting providing shareholder oversight. The company publishes sustainability goals, ESG performance data, and safety, health and wellbeing metrics as part of its public reporting. Community investment is channelled through the Roche Global Citizenship programme, which covers arts and culture, community disaster relief, humanitarian and social development, and science education initiatives. Further information is available at roche.com.